Biotech Voices

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Our contributors are not paid for their opinions.

Have any questions or feedback, or think you have a voice that should be heard? Reach out to Drew Armstrong.

Log in to your account

email

password

request magic link

If you're already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.

email

reset password

We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.

Biotech Voices

Biotech Voices channel feed

Biotech Voices: Coronavirus will change biotech research with remote collaborations

Two years in, Hong Kong’s biotech experiment has been validated

Drug discovery in the age of coronavirus

Biopharma has abandoned antibiotic development. Here’s why we did, too.

Biotech boards burdened: Bridging the success gap

China has become a CEO-level priority for multinational pharmaceutical companies: the trend and the implications

Analysis: In most of the Big Pharma world, R&D spending towers over revenue from new drugs. Guess who beat the odds

Brad Loncar's ASCO19 preview: 5 big ideas to watch for at the ultimate cancer show of the year

The right mix matters in biopharma leadership

Whale watching: What a decade of change at Big Pharma taught us about corporate phenotypes

Pharma’s summer of punk: Who's playing the hits — or taking a hit — on the world innovation tour

Pharma, we have a problem: New drugs can't cover the cost of Big Pharma's failures

May the candle burn forever: Polite reminders about the JPMorgan confab

Guest column: The real cost of drug development

Guest column: The 3 big waves reshaping investment strategies in early-stage biotech

Brad Loncar's ASCO18 preview: Past ASCOs point to the top drugs that will soon elbow for the Oscars of cancer R&D

Pharma's broken business model — Part 2: Scraping the barrel in drug discovery

Elephants can't jump? IDEA's Mike Rea says some Big Pharma players are crushing old beliefs

On this Rare Disease Day, let's all commit to helping recognize the life and work of biotech giant Henri A. Termeer

Pharma's broken business model: An industry on the brink of terminal decline

Visualize: Just how much did biotech unicorn Moderna rely on immigrants to build the staff?

Dear Kite: With 2300% upside, we blazed an amazing trail

Visualize: What would these 11 biotech companies look like without immigrants?

Candid Truths From A Biotech IPO